| Autor: |
Maria Valeria, Freire, Marie, Martin, Romain, Thissen, Cédric, Van Marcke, Karin, Segers, Edith, Sépulchre, Natacha, Leroi, Céline, Lété, Corinne, Fasquelle, Jean, Radermacher, Yeter, Gokburun, Joelle, Collignon, Anne, Sacré, Claire, Josse, Leonor, Palmeira, Vincent, Bours |
| Přispěvatelé: |
UCL - SSS/IREC - Institut de recherche expérimentale et clinique, UCL - (SLuc) Centre du cancer, UCL - (SLuc) Unité d'oncologie médicale |
| Jazyk: |
angličtina |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Frontiers in oncology, Vol. 12, no.1, p. 835581 (2022) |
| Popis: |
ObjectiveThe link between BRCA1 and homologous recombination deficiency (HRD) in cancer has gained importance with the emergence of new targeted cancer treatments, while the available data on the role of the gene in colorectal cancer (CRC) remain contradictory. The aim of this case series was to elucidate the role of known pathogenic BRCA1 variants in the development of early-onset CRC.DesignPatients were evaluated using targeted next generation sequencing, exome sequencing and chromosomal microarray analysis of the paired germline and tumor samples. These results were used to calculate the HRD score and the frequency of mutational signatures in the tumors.ResultsThree patients with metastatic CRC were heterozygous for a previously known BRCA1 nonsense variant. All tumors showed remarkably high HRD scores, and the HRD-related signature 3 had the second highest contribution to the somatic pattern of variant accumulation in the samples (23% in 1 and 2, and 13% in sample 3).ConclusionsA BRCA1 germline pathogenic variant can be involved in CRC development through HRD. Thus, BRCA1 testing should be considered in young patients with a personal history of microsatellite stable CRC as this could further allow a personalized treatment approach. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
